VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Diagnosis of primary immunodeficiency with         │ Diagnosis of primary immunodeficiency with         │     100 │
│ established plan to undergo myeloablative or non-  │ established plan to undergo myeloablative or non-  │         │
│ myeloablative allogeneic hematopoietic stem cell   │ myeloablative allogeneic hematopoietic stem cell   │         │
│ transplant for treatment thereof or diagnosis of a │ transplant for treatment thereof or diagnosis of a │         │
│ form of primary immunodeficiency for which         │ form of primary immunodeficiency for which         │         │
│ hematopoietic stem cell transplantation is not     │ hematopoietic stem cell transplantation is not     │         │
│ indicated                                          │ indicated                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active infection with EBV, CMV, and/or Adenovirus, │ Active infection with EBV, CMV, and/or Adenovirus, │     100 │
│ unable to be successfully controlled with standard │ unable to be successfully controlled with standard │         │
│ therapy                                            │ therapy                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Steroids less than 0.5 mg/kg/day prednisone        │ Steroids less than 0.5 mg/kg/day prednisone        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Karnofsky/Lansky score of ≥ 50                     │ Karnofsky/Lansky score of ≥ 50                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ANC greater than 500/µL                            │ ANC greater than 500/µL                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Negative pregnancy test (if female of childbearing │ Negative pregnancy test (if female of childbearing │     100 │
│ potential)                                         │ potential)                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient or parent/guardian capable of providing    │ Patient or parent/guardian capable of providing    │     100 │
│ informed consent                                   │ informed consent                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with other uncontrolled infections (see   │ Patients with other uncontrolled infections (see   │     100 │
│ 2.3.2 for definitions)                             │ 2.3.2 for definitions)                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who received ATG, Campath, or other T     │ Patients who received ATG, Campath, or other T     │     100 │
│ cell immunosuppressive monoclonal antibodies in    │ cell immunosuppressive monoclonal antibodies in    │         │
│ the last 28 days                                   │ the last 28 days                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Received donor lymphocyte infusion in last 28 days │ Received donor lymphocyte infusion in last 28 days │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosis of Omenn's syndrome or MHC class I       │ Diagnosis of Omenn's syndrome or MHC class I       │     100 │
│ deficiency                                         │ deficiency                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active and uncontrolled malignancy                 │ Active and uncontrolled malignancy                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or lactating                              │ Pregnant or lactating                              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unable to wean steroids to ≤0.5 mg/kg/day          │ Unable to wean steroids to ≤0.5 mg/kg/day          │     100 │
│ prednisone                                         │ prednisone                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with Grade 3 hyperbilirubinemia           │ Patients with Grade 3 hyperbilirubinemia           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Bilirubin \<2x, AST \<3x, Serum creatinine \<2x    │ Bilirubin <2x, AST <3x, Serum creatinine <2x upper │      97 │
│ upper limit of normal, Hgb \>8.0                   │ limit of normal, Hgb >8.0                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pulse oximetry of \> 90% on room air               │ Pulse oximetry of > 90% on room air                │      99 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                       │   Score │
╞═══════════════════════════════════╪═════════════════════════════════════╪═════════╡
│ Must have minimum age of 4 Weeks  │ Pulse oximetry of > 90% on room air │      36 │
├───────────────────────────────────┼─────────────────────────────────────┼─────────┤
│ Must have maximum age of 45 Years │ Pulse oximetry of > 90% on room air │      44 │
╘═══════════════════════════════════╧═════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 97
Average Levenshtein Ratio of individual lines: 93.47368421052632
OverAll Ratio: 95.23684210526315
